{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:09:41Z","timestamp":1792098581715,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T00:00:00Z","timestamp":1448496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T00:00:00Z","timestamp":1448496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/hr.2015.129","type":"journal-article","created":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T07:01:33Z","timestamp":1448521293000},"page":"133-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism"],"prefix":"10.1038","volume":"39","author":[{"given":"Shigehiro","family":"Karashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Kometani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Sawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Seta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyu","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,26]]},"reference":[{"key":"BFhr2015129_CR1","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F . PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronsim in 1125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293\u20132300.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr2015129_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/hr.2010.166","volume":"34","author":"Y Ito","year":"2011","unstructured":"Ito Y, Takeda R, Karashima S, Yamamoto Y, Yoneda T, Takeda Y . Prevalence of primaryaldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 2011; 34: 98\u2013102.","journal-title":"Hypertens Res"},{"key":"BFhr2015129_CR3","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ . Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243\u20131245.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr2015129_CR4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1291\/hypres.27.781","volume":"27","author":"Y Takeda","year":"2004","unstructured":"Takeda Y . Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. Hypertens Res 2004; 27: 781\u2013789.","journal-title":"Hypertens Res"},{"key":"BFhr2015129_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/BF03347840","volume":"18","author":"R Takeda","year":"1995","unstructured":"Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T . Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. J Endocrinol Invest 1995; 18: 370\u2013373.","journal-title":"J Endocrinol Invest"},{"key":"BFhr2015129_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/hr.2013.30","volume":"36","author":"ML Muiesan","year":"2013","unstructured":"Muiesan ML, Salvetti M, Rizzoni D, Paini A, Agabiti-Rosei C, Aggiusti C, Agabiti Rosei E . Resistant hypertension and target organ damage. Hypertens Res 2013; 36: 485\u2013491.","journal-title":"Hypertens Res"},{"key":"BFhr2015129_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","volume":"66","author":"WF Young","year":"2007","unstructured":"Young WF . Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007; 66: 607\u2013618.","journal-title":"Clin Endocrinol"},{"key":"BFhr2015129_CR8","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.beem.2010.10.001","volume":"24","author":"M Quinkler","year":"2010","unstructured":"Quinkler M, Stewart PM . Treatment of primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2010; 24: 923\u2013932.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"BFhr2015129_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","volume":"31","author":"G Colussi","year":"2013","unstructured":"Colussi G, Catena C, Sechi LA . Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary aldosteronism. J Hypertens 2013; 31: 3\u201315.","journal-title":"J Hypertens"},{"key":"BFhr2015129_CR10","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1210\/jc.2005-1733","volume":"91","author":"F Fallo","year":"2006","unstructured":"Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P . Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454\u2013459.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFhr2015129_CR11","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1210\/jc.2006-0736","volume":"91","author":"C Catena","year":"2006","unstructured":"Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA . Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006; 91: 3457\u20133463.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFhr2015129_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","volume":"25","author":"G Giacchetti","year":"2007","unstructured":"Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, Boscaro M . Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007; 25: 177\u2013186.","journal-title":"J Hypertens"},{"key":"BFhr2015129_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/cvr\/cvp191","volume":"84","author":"A Hirata","year":"2009","unstructured":"Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi T, Shimomura I . Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance 1 in obese mice. Cardiovasc Res 2009; 84: 164\u2013172.","journal-title":"Cardiovasc Res"},{"key":"BFhr2015129_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1507\/endocrj.EJ11-0133","volume":"58","author":"T Nishikawa","year":"2011","unstructured":"Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A . Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism\u2013the Japan Endocrine Society 2009. Endocr J 2011; 58: 711\u2013721.","journal-title":"Endocr J"},{"key":"BFhr2015129_CR15","first-page":"1633","volume":"84","author":"Y Takeda","year":"1999","unstructured":"Takeda Y, Furukawa K, Inaba S, Miyamori I, Mabuchi H . Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism. J Clin Endocrinol Metab 1999; 84: 1633\u20131637.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFhr2015129_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1148\/radiology.211.1.r99ap15283","volume":"211","author":"T Yoshizumi","year":"1999","unstructured":"Yoshizumi T, Nakamura T, Yamane M, Islam AHMW, Menju M, Yamasaki K . Abdominal fat: standardized technique for measurement at CT. Radiology 1999; 211: 283\u2013286.","journal-title":"Radiology"},{"key":"BFhr2015129_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/hr.2012.182","volume":"36","author":"A Sato","year":"2013","unstructured":"Sato A . Mineralocorticoid receptor antagonists: their use and differentiation in Japan. Hypertens Res 2013; 36: 185\u2013190.","journal-title":"Hypertens Res"},{"key":"BFhr2015129_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","volume":"217","author":"SM Garthwaite","year":"2004","unstructured":"Garthwaite SM, McMahon EG . The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004; 217: 27\u201331.","journal-title":"Mol Cell Endocrinol"},{"key":"BFhr2015129_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ . Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709\u2013716.","journal-title":"Am J Hypertens"},{"key":"BFhr2015129_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1517\/14656566.9.4.509","volume":"9","author":"A Karagiannis","year":"2008","unstructured":"Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, Anagnostis P, Athyros VG, Mikhailidis DP . Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008; 9: 509\u2013515.","journal-title":"Expert Opin Pharmacother"},{"key":"BFhr2015129_CR21","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","volume":"29","author":"HK Parthasarathy","year":"2011","unstructured":"Parthasarathy HK, Menard J, White WB, Young WF Jr, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM, MacDonald TM . A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29: 980\u2013990.","journal-title":"J Hypertens"},{"key":"BFhr2015129_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1677\/ERC-08-0094","volume":"15","author":"A Karagiannis","year":"2008","unstructured":"Karagiannis A, Tziomalos K, Kakafika AI, Athyros VG, Harsoulis F, Mikhailidis DP . Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. Endocr Relat Cancer 2008; 15: 693\u2013700.","journal-title":"Endocr Relat Cancer"},{"key":"BFhr2015129_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/HJH.0b013e32835b71d6","volume":"31","author":"PM Jansen","year":"2013","unstructured":"Jansen PM, Frenkel WJ, van den Born BJ, de Bruijne EL, Deinum J, Kerstens MN, Arnoldus JH, Woittiez AJ, Wijbenga JA, Zietse R, Danser AH, van den Meiracker AH . Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension. J Hypertens 2013; 31: 404\u2013413.","journal-title":"J Hypertens"},{"key":"BFhr2015129_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejphar.2008.12.041","volume":"605","author":"T Isaka","year":"2009","unstructured":"Isaka T, Ikeda K, Takada Y, Inada Y, Tojo K, Tajima N . Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2009; 605: 49\u201352.","journal-title":"Eur J Pharmacol"},{"key":"BFhr2015129_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/hr.2010.221","volume":"34","author":"M Abe","year":"2011","unstructured":"Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, Matsumoto K, Soma M . Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertens Res 2011; 34: 268\u2013273.","journal-title":"Hypertens Res"},{"key":"BFhr2015129_CR26","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/hr.2011.35","volume":"34","author":"T Nakamura","year":"2011","unstructured":"Nakamura T, Fukuda M, Kataoka K, Nako H, Tokutomi Y, Dong YF, Yamamoto E, Yasuda O, Ogawa H, Kim-Mitsuyama S . Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats. Hypertens Res 2011; 34: 817\u2013824.","journal-title":"Hypertens Res"},{"key":"BFhr2015129_CR27","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1096\/fj.06-7970com","volume":"21","author":"M Caprio","year":"2007","unstructured":"Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC . Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007; 21: 2185\u20132194.","journal-title":"FASEB J"},{"key":"BFhr2015129_CR28","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","volume":"59","author":"AM Briones","year":"2012","unstructured":"Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Correa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM . Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012; 59: 1069\u20131078.","journal-title":"Hypertension"},{"key":"BFhr2015129_CR29","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1210\/jc.2005-1733","volume":"91","author":"F Fallo","year":"2006","unstructured":"Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P . Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454\u2013459.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFhr2015129_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1161\/01.HYP.0000137982.10191.0a","volume":"44","author":"AM Sironi","year":"2004","unstructured":"Sironi AM, Gastaldelli A, Mari A, Ciociaro D, Positano V, Buzzigoli E, Ghione S, Turchi S, Lombardi M, Ferrannini E . Visceral fat in hypertension, influence on insulin resistance and \u03b2-cell function. Hypertension 2004; 44: 127\u2013133.","journal-title":"Hypertension"},{"key":"BFhr2015129_CR31","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","volume":"4","author":"W Kosmala","year":"2011","unstructured":"Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH . A randomized study of the beneficial effects of aldosterone antagonist on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging 2011; 4: 1239\u20131249.","journal-title":"JACC Cardiovasc Imaging"},{"key":"BFhr2015129_CR32","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.amjhyper.2007.09.001","volume":"20","author":"T Yoneda","year":"2007","unstructured":"Yoneda T, Takeda Y, Usukura M, Oda N, Takata H, Yamamoto Y, Karashima S, Yamagishi M . Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens 2007; 20: 1329\u20131333.","journal-title":"Am J Hypertens"},{"key":"BFhr2015129_CR33","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","volume":"47","author":"M Nagase","year":"2006","unstructured":"Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T . Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006; 47: 1084\u20131093.","journal-title":"Hypertension"},{"key":"BFhr2015129_CR34","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1210\/jc.2013-2180","volume":"99","author":"Y Iwakura","year":"2014","unstructured":"Iwakura Y, Morimoto R, Kudo M, Ono Y, Takase K, Seiji K, Arai Y, Nakamura Y, Sasano H, Ito S, Satoh F . Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab 2014; 99: 1593\u20131598.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFhr2015129_CR35","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","volume":"2","author":"K Ando","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T . for the EVALUATE Study Group. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomized, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2: 944\u2013953.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"BFhr2015129_CR36","doi-asserted-by":"publisher","first-page":"H2241","DOI":"10.1152\/ajpheart.2001.281.5.H2241","volume":"281","author":"J Francis","year":"2001","unstructured":"Francis J, Weiss RM, Wei SG, Johnson AK, Beltz TG, Zimmerman K, Felder RB . Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol 2001; 281: H2241\u2013H2251.","journal-title":"Am J Physiol Heart Circ Physiol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr2015129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2015129","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2015129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:15:01Z","timestamp":1684430101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr2015129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,26]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["BFhr2015129"],"URL":"https:\/\/doi.org\/10.1038\/hr.2015.129","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,26]]},"assertion":[{"value":"26 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}